Arcus Biosciences Says New Data Demonstrated Best-In-Class Potential For Casdatifan, A HIF-2a Inhibitor, In Patients With Metastatic Kidney Cancer; A 9.7-Month Median Progression-Free Survival Was Reached For The 50mg Twice-Daily Casdatifan Monotherapy Co